Eduardo Rios-Garcia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eduardo Rios-Garcia has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Oscar Arrieta
Department of Medical Oncology Instituto Nacional de Cancerología Mexico City
29 shared publications - Ana I. Velazquez
University of California, San Francisco, CA
23 shared publications - Andreia Cristina de Melo
Brazilian National Cancer Institute (INCA), Division of Clinical Research and Technological Development, Rio de Janeiro, Brazil
23 shared publications - Andres Felipe Cardona
Thoracic Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia
23 shared publications - Christian Rolfo
The Ohio State University Comprehensive Cancer Center, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), Columbus, OH, USA
23 shared publications - Erick Figueiredo Saldanha
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada; Harvard T. H. Chan School, Harvard University, Boston, MA
23 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (10)
Independent cancer research in low- and middle-income countries: why it matters and how to build it
By 2030, an estimated 75% of cancer deaths will occur in low- and middle-income countries (LMICs). Weak surveillance systems and limited research infrastructure often hide the true magnitude of this burden. Thus, independent, locally led research is essential for generating high-quality data, addressing regional disease patterns, and informing context-specific strategies for cancer control. Low national investment, heavy reliance on industry-sponsored trials, and a scarcity of trained clinician scientists hinder independent cancer research in LMICs. In this narrative review, we synthesize the published literature and present a descriptive analysis of oncology trials registered on ClinicalTrials.gov (accessed July 2025), categorized by country, funding source, and tumor site and normalized to disease burden, drawing on illustrative examples from Africa, Asia, and Latin America. We highlight the transformative impact of context-sensitive research initiatives, explore disparities in sponsorship by country and tumor type, and outline ways to strengthen the research infrastructure. These include the establishment of population-based cancer registries, regional funding mechanisms, streamlined regulatory frameworks, and workforce development through formal research training and protected time. Finally, we propose strategies to enhance international collaboration and amplify LMIC participation in setting global cancer research priorities.
- 7 September 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (10)
Open AccessIndependent cancer research in low- and middle-income countries: why it matters and how to build it
By 2030, an estimated 75% of cancer deaths will occur in low- and middle-income countries (LMICs). Weak surveillance systems and limited research infrastructure often hide the true magnitude of this burden. Thus, independent, locally led research is essential for generating high-quality data, addressing regional disease patterns, and informing context-specific strategies for cancer control. Low national investment, heavy reliance on industry-sponsored trials, and a scarcity of trained clinician scientists hinder independent cancer research in LMICs. In this narrative review, we synthesize the published literature and present a descriptive analysis of oncology trials registered on ClinicalTrials.gov (accessed July 2025), categorized by country, funding source, and tumor site and normalized to disease burden, drawing on illustrative examples from Africa, Asia, and Latin America. We highlight the transformative impact of context-sensitive research initiatives, explore disparities in sponsorship by country and tumor type, and outline ways to strengthen the research infrastructure. These include the establishment of population-based cancer registries, regional funding mechanisms, streamlined regulatory frameworks, and workforce development through formal research training and protected time. Finally, we propose strategies to enhance international collaboration and amplify LMIC participation in setting global cancer research priorities.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Cancer Incidence and Mortality Estimates in Latin America and the Caribbean: A Systematic Analysis of the GLOBOCAN 2022
Table S5. Linear Regression Between Human Development Index (HDI) and Cancer Burden Indicators (1990–2022)
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Cancer Incidence and Mortality Estimates in Latin America and the Caribbean: A Systematic Analysis of the GLOBOCAN 2022
Table S5. Linear Regression Between Human Development Index (HDI) and Cancer Burden Indicators (1990–2022)
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Cancer Incidence and Mortality Estimates in Latin America and the Caribbean: A Systematic Analysis of the GLOBOCAN 2022
HDI and ASMR vs. HDI in 2022. A, Plot displaying the relationship between HDI and ASMR. B, Map of HDI distribution across LAC countries.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Cancer Incidence and Mortality Estimates in Latin America and the Caribbean: A Systematic Analysis of the GLOBOCAN 2022
HDI and ASMR vs. HDI in 2022. A, Plot displaying the relationship between HDI and ASMR. B, Map of HDI distribution across LAC countries.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Cancer Incidence and Mortality Estimates in Latin America and the Caribbean: A Systematic Analysis of the GLOBOCAN 2022
Table S6. Estimated incident cancer cases and deaths for 2022 and projected values for 2050, stratified by cancer type and sex.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Cancer Incidence and Mortality Estimates in Latin America and the Caribbean: A Systematic Analysis of the GLOBOCAN 2022
Table S6. Estimated incident cancer cases and deaths for 2022 and projected values for 2050, stratified by cancer type and sex.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Cancer Incidence and Mortality Estimates in Latin America and the Caribbean: A Systematic Analysis of the GLOBOCAN 2022
Absolute counts of early-onset cancer cases and deaths, age-standardized incidence (ASIR) and mortality (ASMR) rates, and Human Development Index (HDI) values, stratified by country and gender, 2022.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Cancer Incidence and Mortality Estimates in Latin America and the Caribbean: A Systematic Analysis of the GLOBOCAN 2022
Absolute counts of early-onset cancer cases and deaths, age-standardized incidence (ASIR) and mortality (ASMR) rates, and Human Development Index (HDI) values, stratified by country and gender, 2022.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Cancer Incidence and Mortality Estimates in Latin America and the Caribbean: A Systematic Analysis of the GLOBOCAN 2022
ASMR in LAC countries by cancer type, 1990–2022. A, Prostate cancer in males. B, Breast cancer in females. C, Colorectal cancer in males. D, Colorectal cancer in females. E, Lung cancer in males. F, Lung cancer in females.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Cancer Incidence and Mortality Estimates in Latin America and the Caribbean: A Systematic Analysis of the GLOBOCAN 2022
ASMR in LAC countries by cancer type, 1990–2022. A, Prostate cancer in males. B, Breast cancer in females. C, Colorectal cancer in males. D, Colorectal cancer in females. E, Lung cancer in males. F, Lung cancer in females.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Cancer Incidence and Mortality Estimates in Latin America and the Caribbean: A Systematic Analysis of the GLOBOCAN 2022
Figure S3. Projected cases and deaths numbers (per 1,000 persons) under varying global rate-change scenarios in patients with early-onset cancer, 2022–2050.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Cancer Incidence and Mortality Estimates in Latin America and the Caribbean: A Systematic Analysis of the GLOBOCAN 2022
Figure S3. Projected cases and deaths numbers (per 1,000 persons) under varying global rate-change scenarios in patients with early-onset cancer, 2022–2050.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Cancer Incidence and Mortality Estimates in Latin America and the Caribbean: A Systematic Analysis of the GLOBOCAN 2022
Figure S6. Bar plots of ASIR and ASMR in 2022 for all countries and cancer types in patients with 15-39 years.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Cancer Incidence and Mortality Estimates in Latin America and the Caribbean: A Systematic Analysis of the GLOBOCAN 2022
Figure S6. Bar plots of ASIR and ASMR in 2022 for all countries and cancer types in patients with 15-39 years.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Cancer Incidence and Mortality Estimates in Latin America and the Caribbean: A Systematic Analysis of the GLOBOCAN 2022
Figure S4. ASMR in LAC countries by age group and sex. All sites excluding non-melanoma skin cancer, 1990–2022.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Cancer Incidence and Mortality Estimates in Latin America and the Caribbean: A Systematic Analysis of the GLOBOCAN 2022
Figure S4. ASMR in LAC countries by age group and sex. All sites excluding non-melanoma skin cancer, 1990–2022.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Cancer Incidence and Mortality Estimates in Latin America and the Caribbean: A Systematic Analysis of the GLOBOCAN 2022
Figure S2. Cancer types by ASIR and ASMR in 2022 in patients with early-onset cancer.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Cancer Incidence and Mortality Estimates in Latin America and the Caribbean: A Systematic Analysis of the GLOBOCAN 2022
Figure S2. Cancer types by ASIR and ASMR in 2022 in patients with early-onset cancer.